Ex­clu­sive: Cel­lens rais­es .5M to ad­vance physics-based test for blad­der can­cer
Boston-based com­pa­ny Cel­lens se­cured .5 mil­lion to de­vel­op its plat­form that de­tects blad­der can­cer through an ap­proach that com­bines physics and AI,
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Hims launch­es lab test­ing for pre­ven­tive care
Ex­clu­sive: Ex-Il­lu­mi­na and Grail em­ploy­ees raise .7M to spot liv­er dis­ease
10x Ge­nomics sues DNA gi­ant Il­lu­mi­na over patents
Client Engagement Mgr - Life Sciences Strategy & Intelligence
Up­dat­ed: Pfiz­er dis­clos­es pa­tient death in Hym­pa­vzi he­mo­phil­ia tri­al
Drug­mak­ers with White House MFN deals claim ex­emp­tion from pro­posed Medicare pric­ing tests
No­vo Nordisk eyes a strong launch with FDA ap­proval of obe­si­ty pill
Neu­ro­crine’s In­grez­za flunks piv­otal study in dys­k­i­net­ic cere­bral pal­sy
Gilead­'s her­pes deal; FDA ap­provals for Boehringer, Roche
The End­points win­ners and losers list: Who was up and who was down in 2025